All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub spoke to the Steering Committee Chair, Jean-Jacques Kiladjian, Université de Paris, Paris, FR. We asked, When can we safely discontinue interferon alpha therapy in patients with myeloproliferative neoplasms?
When can we safely discontinue interferon alpha therapy in patients with MPN?
Kiladjian reports the results of a study comparing the clinical outcome of patients with myeloproliferative neoplasms who discontinued therapy after at least three months of interferon alpha treatment to patients who continued interferon alpha treatment despite achieving a complete hematological remission.
SIMPLIFY-1+2 trial: What is the long-term benefit of momelotinib treatment in R/R MF?
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub spoke to Ruben Mesa, UT Health San Antonio, San Antonio, US. We...
Interferon therapy in the management of myeloproliferative neoplasms
Treatment with interferon (IFN) therapy is considered successful for patients with myeloproliferative neoplasms (MPN), such as polycythemia vera (PV) and essential thrombocythemia...
Subscribe to get the best content related to MPN delivered to your inbox